Q1 2025 Earnings Forecast for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Issued By HC Wainwright

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – HC Wainwright issued their Q1 2025 EPS estimates for shares of ORIC Pharmaceuticals in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($0.47) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.97) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.49) EPS for the quarter, meeting analysts’ consensus estimates of ($0.49).

ORIC has been the topic of a number of other reports. Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals in a research report on Friday, February 23rd. They set an “overweight” rating on the stock. Wedbush raised their price target on shares of ORIC Pharmaceuticals from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, March 1st. JPMorgan Chase & Co. decreased their price objective on shares of ORIC Pharmaceuticals from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, March 27th. Finally, Citigroup dropped their target price on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $20.00.

ORIC Pharmaceuticals Trading Down 1.0 %

Shares of ORIC opened at $9.50 on Friday. The company has a market cap of $640.49 million, a price-to-earnings ratio of -4.85 and a beta of 1.19. The business’s fifty day simple moving average is $11.78 and its two-hundred day simple moving average is $9.96. ORIC Pharmaceuticals has a 12 month low of $4.91 and a 12 month high of $16.65.

Institutional Investors Weigh In On ORIC Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. AJOVista LLC bought a new position in shares of ORIC Pharmaceuticals in the 4th quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. purchased a new stake in ORIC Pharmaceuticals during the fourth quarter valued at approximately $58,000. Strs Ohio bought a new position in ORIC Pharmaceuticals in the fourth quarter worth approximately $72,000. Sherbrooke Park Advisers LLC bought a new position in ORIC Pharmaceuticals in the third quarter worth approximately $72,000. Finally, Algert Global LLC purchased a new position in shares of ORIC Pharmaceuticals during the 3rd quarter worth $81,000. 95.05% of the stock is currently owned by institutional investors.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.